{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T23:02:58Z","timestamp":1744671778030},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,11]]},"DOI":"10.7759\/cureus.17106","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T20:26:17Z","timestamp":1628713577000},"source":"Crossref","is-referenced-by-count":2,"title":["A Difficult and Rare Case of Warfarin Refractory Antiphospholipid Syndrome Presenting With Catastrophic Antiphospholipid Syndrome Complicated by Gastrointestinal Bleeding"],"prefix":"10.7759","author":[{"given":"William","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foma","family":"Munoh Kenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Shulimovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00005","article-title":"Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients","volume":"82","author":"Espinosa G","year":"2003","unstructured":"Espinosa G, Santos E, Cervera R, et al.. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore). 2003, 82:106-18. 10.1097\/00005792-200303000-00005","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"Lim W","year":"2013","unstructured":"Lim W. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2013, 2013:675-80. 10.1182\/asheducation-2013.1.675","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129627","article-title":"How we diagnose the antiphospholipid syndrome","volume":"113","author":"Giannakopoulos B","year":"2009","unstructured":"Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009, 113:985-94. 10.1182\/blood-2007-12-129627","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature","volume":"18","author":"Dufrost V","year":"2016","unstructured":"Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016, 18:74. 10.1007\/s11926-016-0623-7","journal-title":"Curr Rheumatol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo V","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, et al.. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018, 132:1365-71. 10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185132","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban","volume":"103","author":"Martinelli I","year":"2018","unstructured":"Martinelli I, Abbattista M, Bucciarelli P, et al.. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018, 103:e315-7. 10.3324\/haematol.2017.185132","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros J","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019, 171:685-94. 10.7326\/M19-0291","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi G","year":"2005","unstructured":"Finazzi G, Marchioli R, Brancaccio V, et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005, 3:848-53. 10.1111\/j.1538-7836.2005.01340.x","journal-title":"J Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther MA","year":"2003","unstructured":"Crowther MA, Ginsberg JS, Julian J, et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003, 349:1133-8. 10.1056\/NEJMoa035241","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01516.x","article-title":"Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy","volume":"3","author":"Dentali F","year":"2005","unstructured":"Dentali F, Manfredi E, Crowther M, Ageno W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005, 3:2121-3. 10.1111\/j.1538-7836.2005.01516.x","journal-title":"J Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"Erkan D","year":"2010","unstructured":"Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010, 10:74-9. 10.1016\/j.autrev.2010.08.005","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli S","year":"2006","unstructured":"Bucciarelli S, Espinosa G, Cervera R, et al.. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006, 54:2568-76. 10.1002\/art.22018","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200111000-00002","article-title":"Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients","volume":"80","author":"Asherson RA","year":"2001","unstructured":"Asherson RA, Cervera R, Piette JC, et al.. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001, 80:355-77. 10.1097\/00005792-200111000-00002","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients","volume":"77","author":"Asherson RA","year":"1998","unstructured":"Asherson RA, Cervera R, Piette JC, et al.. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998, 77:195-207. 10.1097\/00005792-199805000-00005","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force Report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera R","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Colafrancesco S, et al.. 14th International Congress on Antiphospholipid Antibodies Task Force Report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014, 13:699-707. 10.1016\/j.autrev.2014.03.002","journal-title":"Autoimmun Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314540764","article-title":"Catastrophic antiphospholipid syndrome: task force report summary","volume":"23","author":"Cervera R","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I. Catastrophic antiphospholipid syndrome: task force report summary. Lupus. 2014, 23:1283-5. 10.1177\/0961203314540764","journal-title":"Lupus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65145-a-difficult-and-rare-case-of-warfarin-refractory-antiphospholipid-syndrome-presenting-with-catastrophic-antiphospholipid-syndrome-complicated-by-gastrointestinal-bleeding","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:18Z","timestamp":1707506898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65145-a-difficult-and-rare-case-of-warfarin-refractory-antiphospholipid-syndrome-presenting-with-catastrophic-antiphospholipid-syndrome-complicated-by-gastrointestinal-bleeding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.17106","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,11]]}}}